TY - JOUR
T1 - Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation
AU - ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation
AU - Yoshimitsu, Makoto
AU - Tanosaki, Ryuji
AU - Kato, Koji
AU - Ishida, Takashi
AU - Choi, Ilseung
AU - Takatsuka, Yoshifusa
AU - Fukuda, Takahiro
AU - Eto, Tetsuya
AU - Hidaka, Michihiro
AU - Uchida, Naoyuki
AU - Miyamoto, Toshihiro
AU - Nakashima, Yasuhiro
AU - Moriuchi, Yukiyoshi
AU - Nagafuji, Koji
AU - Miyazaki, Yasuhiko
AU - Ichinohe, Tatsuo
AU - Takanashi, Minoko
AU - Atsuta, Yoshiko
AU - Utsunomiya, Atae
N1 - Publisher Copyright:
© 2017 The American Society for Blood and Marrow Transplantation
PY - 2018/4
Y1 - 2018/4
N2 - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.
AB - Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients.
UR - http://www.scopus.com/inward/record.url?scp=85039424663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039424663&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2017.11.005
DO - 10.1016/j.bbmt.2017.11.005
M3 - Article
C2 - 29155320
AN - SCOPUS:85039424663
SN - 1083-8791
VL - 24
SP - 832
EP - 839
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 4
ER -